Exploring the Breakthroughs of Mitapivat in Non-Transfusion-Dependent Alpha- or Beta-Thalassemia: Insights from the Phase 3 ENERGIZE Study

Executed on:Feb 6, 2024 1:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Howard UniversityProfessor of Medicine and Microbiology/Immunology & Director or the Center for Sickle Cell Disease at Howard University (previously held positions at the NIH and Johns Hopkins).
Manages 355 patients with Sickle Cell Disease, 2 active Beta-Thalassemia patients and 1 HbH disease patient.
Research interests include the use of genetic tools to understand and treat sickle cell disease and complications of transfusion therapy.

Interview Goal

This interview aims to delve into the pivotal findings from the Phase 3 ENERGIZE trial of Mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia. We will discuss the drug's efficacy, safety, and its potential role in changing the treatment landscape for thalassemia, as well as its implications for future therapies in rare hematologic diseases.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.